PR86552

SINGAPORE, Nov. 11, 2020 /PRNewswire=KYODO JBN/ --

Following GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK)'s

cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit has received

provisional authorization by Health Science Authority (HSA) Singapore on 8th

May 2020, CE-IVD marking in Europe on 26th May 2020 and FDA approval in

Philippines for commercial use on 11th August 2020.

U.S. Food and Drug Administration (FDA) issued an emergency use authorization

(EUA) for cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit on 6th

November 2020.

cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit which is co-

developed with Duke-NUS Medical School Singapore and Diagnostics Development

Hub from Singapore's Agency for Science, Technology and Research (A*STAR) and

manufactured by GenScript Biotech Corporation, is the first serology test

authorized to detect neutralizing antibodies – the specific antibodies present

in the serum of COVID-19 patients that are responsible for clearing the viral

infection, without the need of live biological materials and biocontainment

facility. The test measures the presence of neutralizing antibodies in patients

recovering from COVID-19 or receiving a vaccine.

GenScript has started to serve global market through authorized distributors

and authorized laboratories to provide the test to public. GenScript promised

to support the healthcare community and continue the fight against COVID-19.

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology

group. Based on its leading gene synthesis technology, GenScript has developed

four major platforms including the global cell therapy platform, the biologics

contract development and manufacturing organization (CDMO) platform, the

contract research organization (CRO) platform and the industrial synthesis

product platform.

GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong

Stock Exchange in 2015. GenScript's business operation spans over 100 countries

and regions worldwide, with legal entities located in the U.S., Mainland China,

Hong Kong, Japan, Singapore, Netherlands and Ireland. GenScript has provided

premium, convenient, and reliable products and services for over 100,000 customers.

GenScript has a number of intellectual property rights and technical secrets,

including more than 100 patents and over 270 patent applications. As of June

30, 2020, GenScript's products and services have been cited by 51,000

peer-reviewed journal articles worldwide.

SOURCE Genscript